Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01250496 · ClinicalTrials.gov registry record · Phase 4
Study With Aminophylline to Attenuate of the Side Effects of Regadenoson
A Phase 4 study, sponsored by Rush University Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 248
- Enrollment target
NCT01250496 is a Phase 4 study that was terminated before completion, run by Rush University Medical Center. The registered enrollment target is 248 participants.
The verdict
NCT01250496, a Phase 4 study, was terminated before completion, sponsored by Rush University Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 248 participants
- Enrollment target
Study Summary
The routine administration of 75 mg of intravenous aminophylline following regadenoson (Lexiscan®), a commonly used medication for nuclear stress testing of the heart, can reduce the gastrointestinal (diarrhea and stomach upset) and other side effects related to regadenoson.
Interventions
- DRUG Placebo
- DRUG Aminophylline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01250496
The ClinicalTrials.gov registry entry for NCT01250496 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01250496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01250496 about?
NCT01250496 is a clinical study titled "Study With Aminophylline to Attenuate of the Side Effects of Regadenoson". The routine administration of 75 mg of intravenous aminophylline following regadenoson (Lexiscan®), a commonly used medication for nuclear stress testing of the heart, can reduce the gastrointestinal (diarrhea and stomach upset) and other side effects related to regadenoson.
What is the current status of trial NCT01250496?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 248 participants. The study started on 2010-11. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01250496?
The interventions under investigation include: Placebo (DRUG), Aminophylline (DRUG).
Who is sponsoring clinical trial NCT01250496?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.